Polymorphism in Diazepam Metabolism in Wistar Rats

Journal of Pharmaceutical Sciences

Volumn 93, Issue 5, 2004, Pages 1271-1278

  Saito, Konomu ^a   Kim, Hyung Sub ^a   Sakai, Noriaki ^a   Ishizuka, Mayumi ^a   Kazusaka, Akio ^a   Fujita, Shoichi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Cytochrome P450; Diazepam; Diazepam p hydroxylation; Extensive metabolizer; Polymorphism; Poor metabolizer

Indexed keywords

CYTOCHROME P450 2C11; CYTOCHROME P450 2D1; CYTOCHROME P450 3A2; DIAZEPAM;

ANIMAL TISSUE; ARTICLE; CATALYSIS; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; GENETIC POLYMORPHISM; LIVER MICROSOME METABOLISM; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT;

EID: 1942530734     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20050     Document Type: Article

References (27)

1. Sloan TP, Mahgoub A, Lancaster R, Idle JR, Smith RL. 1978. Polymorphism of carbon oxidation of drugs and clinical implications. Br Med J 2:655-657.
2. Al-Dabbagh SG, Idle JR, Smith RL. 1981. Animal modelling of human polymorphic drug oxidation - The metabolism of debrisoquine and phenacetin in rat inbred strains. J Pharm Pharmacol 33:161-164.
3. Zysset T, Zeugin T, Kupfer A. 1988. In-vivo and in-vitro dextromethorphan metabolism in SD and DA rat. An animal model of the debrisoquine-type polymorphic oxidation in man. Biochem Pharmacol 15:3155-3160.
4. Mikus G, Trausch B, Rodewald C, Hofmann U, Richter K, Gramatte T, Eichelbaum M. 1997. Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. Clin Pharmacol Ther 61: 459-466.
5. Yamamoto Y, Tasaki T, Nakamura A, Iwata H, Kazusaka A, Gonzalez FJ, Fujita S. 1998. Molecular basis of the Dark Agouti rat drug oxidation polymorphism: Importance of CYP2D1 and CYP2D2. Pharmacogenetics 8:73-82.
6. Schulz-Utermoehl T, Bennett AJ, Ellis SW, Tucker GT, Boobis AR, Edwards RJ. 1999. Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression. Pharmacogenetics 9:357-366.
7. Coller JK, Somogyi AA, Bochner F. 1999. Comparison of (S)-mephenytoin and proguanil oxidation in vitro: Contribution of several CYP isoforms. Br J Clin Pharmacol 48:158-167.
8. Tassaneeyakul W, Tawalee A, Tassaneeyakul W, Kukongviriyapan V, Blaisdell J, Goldstein JA, Gaysornsiri D. 2002. Analysis of the CYP2C19 polymorphism in a North-eastern Thai population. Pharmacogenetics 12:221-225.
9. Beischlag TV, Kalow W, Mahon WA, Inaba T. 1992. Diazepam metabolism by rat and human liver in vitro: Inhibition by mephenytoin. Xenobiotica 22:559-567.
10. Inaba T, Tait A, Nakano M, Mahon WA, Kalow W. 1988. Metabolism of diazepam in vitro by human liver. Independent variability of N-demethylation and C3-hydroxylation. Drug Metab Dispos 16:605-608.
11. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Sawe J, Villen T. 1989. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 45:348-355.
12. Sohn DR, Kusaka M, Ishizaki T, Shin SG, Jang IJ, Shin JG, Chiba K. 1992. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 52:160-169.
13. Wan J, Xia H, He N, Lu YQ, Zhou HH. 1996. The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. Br J Clin Pharmacol 42:471-474.
14. Yang TJ, Krausz KW, Sai Y, Gonzalez FJ, Gelboin HV. 1999. Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism. Drug Metab Dispos 27:102-109.
15. Krausz KW, Goldfarb I, Buters JT, Yang TJ, Gonzalez FJ, Gelboin HV. 2001. Monoclonal anti bodies specific and inhibitory to human cytochromes P450 2C8, 2C9, and 2C19. Drug Metab Dispos 29:1410-1423.
16. Omura T, Sato R. 1964. The carbon monoxide-binding pigment of liver microsomes. J Biol Chem 239:2370-2378.
17. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
18. Fujita S, Chiba M, Ohta M, Kitani K, Suzuki T. 1990. Alteration of plasma sex hormone levels associated with old age and its effect on hepatic drug metabolism in rats. J Pharmacol Exp Ther 253:369-374.
19. Fujita S, Tatsuno J, Kitani K, Suzuki T. 1990. Age-associated alterations in diazepam metabolizing enzyme activities in male and female rats. Drug Metab Dispos 18:812-814.
20. Fujita S, Kitagawa H, Ishizawa H, Suzuki T, Kitani K. 1985. Age-associated alterations in hepatic glutathione-S-taransferaces. Biochem Pharmacol 34: 3891-3894.
21. Neville CF, Ninomiya S, Shimada N, Kamataki T, Imaoka S, Funae Y. 1993. Characterization of specific cytochrome P450 enzymes responsible for the metabolism of diazepam in hepatic microsomes of adult male rats. Biochem Pharmacol 45: 59-65.
22. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature 227:680-685.
23. Towbin H, Staehelin T, Gordon J. 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheet: Procedure and some applications. Proc Natl Acad Sci USA 76:4350-4354.
24. Lennard PR. 1990. Image analysis for all. Nature 347:103-104.
25. van der Laan JW, de Groot G, Wortelboer H, Noordhoek J. 1993. Pharmacokinetic differences of desmethyldiazepam in three outbred Wistar strains related to differences in liver enzyme activities. Pharmacol Toxicol 73:229-232.
26. van der Laan JW, de Boer SF, van der Gugten J, de Groot G. 1991. Differences in the duration of sedative and anxiolytic effects of desmethyldiazepam in two outbred Wistar strains. Pharmacol Biochem Behav 39:149-153.
27. Guengerich FP. 1997. Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chem Biol Interact 106:161-182.